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the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It
regulates many inflammatory processes by cleaving several transmembrane proteins, including
tumour necrosis factor alpha (TNF) and its receptors tumour necrosis factor alpha receptor 1
and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several
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inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes
and cancer as well as neurological and immune diseases. This review summarizes the latest
discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the
role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies
that have investigated its expression and protein activity. The multitude of substrates cleaved
by TACE make this enzyme an attractive target for therapy and a candidate for biomarker
research and development in CAD.
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Résumé L’enzyme de conversion du facteur alpha de nécrose tumorale (TACE/ADAM17),
membre de la famille des A désintégrines et métalloprotéinases (ADAM) qui sont des protéi-
nases clivant l’ectodomaine des protéines transmembrannaires, régule différents processus
inflammatoires en clivant des protéines transmembrannaires, y comrpis le facteur alpha de
nécrose tumorale (TNF) et ses récepteurs 1 et 2. Différentes études ont montré l’association de
TACE avec des maladies inflammatoires tel que l’ischémie, l’insuffisance cardiaque, l’arthrite,
l’athérosclérose, le diabète, le cancer ainsi que des maladies neurologiques et immunologiques.
Cette revue résume les dernières découvertes concernant le mécanisme d’action et de régula-
tion de TACE ainsi que son rôle dans l’athérosclerose et les maladies coronariennes en mettant
en évidence les études cliniques les plus récentes en relation avec son expression et son activ-
ité. La multitude des substrats clivés par TACE rendent cette enzyme une cible thérapeutique
intéressante surtout dans le domaine du développement des biomarqueurs pour les maladies
coronariennes.
Crown Copyright © 2017 Publie´ par Elsevier Masson SAS. Tous droits re´serve´s.
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umour necrosis factor alpha converting enzyme (TACE),
lso known as A disintegrin and metalloproteinase 17
ADAM17), is a membrane-anchored protein responsible
or the ectodomain shedding of a variety of transmem-
rane proteins, such as cytokines, chemokines, and
rowth factors and their receptors. Shedding results in
he initiation or inhibition of downstream signalling and
ellular responses, and is associated with several major
cute and chronic inflammatory diseases. Recent studies
ave reported overexpression of TACE in patients with
oronary artery disease (CAD) as well as after acute
yocardial infarction (AMI), indicating that TACE may be
useful cardiac prognostic biomarker of cardiac events.
his review summarizes recent findings on TACE activity
nd regulation, with an emphasis on the role of TACE in
AD.
tructure
lack et al. first described TACE in 1997 when working with
ammalian THP1 cells, as the enzyme that cleaves tumour
ecrosis factor alpha (TNF), and reported purification andPlease cite this article in press as: Chemaly M, et al. Ro
(TACE/ADAM17) and associated proteins in coronary artery d
https://doi.org/10.1016/j.acvd.2017.08.002
loning of the protein [1]. Subsequently, different forms of
ACE have been described including the full-length protein
∼110 KDa under non-reducing conditions), a mature form
f TACE lacking the prodomain (80 KDa), and a third form
A
T
ketected in cell lysates, which lacks the cytoplasmic domain
60 KDa) [2] (Fig. 1).
ocalization
mmunohistochemical studies suggest that most of the
ctive form of TACE is localized in the cellular perinuclear
egion, with a small amount present on the plasma mem-
rane surface [2]. Tellier et al. further reported that TACE
s sequestered into lipid rafts (Fig. 2). This spatial distribu-
ion has a role in the regulation of TACE activity by keeping
he enzyme separate from its substrates [3].
Lipid rafts are known to have high concentrations of
holesterol, and interestingly, the shedding of TACE sub-
trates, such as CD30 [4], interleukin-6 receptor (IL-6R) [5]
nd L-selectin (CD62L) [6], can be increased by cholesterol-
owering drugs. The increase in TACE shedding was also
bserved with TNF, TNF receptor 1 (TNFR1) and TNF recep-
or 2 (TNFR2) after membrane cholesterol depletion [3].
isruption of the lipid rafts may displace the mature form of
ACE in the non-raft region of the membrane that contains
he major part of TACE substrates, and increase their shed-
ing. Therefore, under normal conditions, the sequestration
f the mature form of TACE in lipid rafts can be considered
s the rate-limiting process of its shedding activity [7].le of tumour necrosis factor alpha converting enzyme
isease and cardiac events. Arch Cardiovasc Dis (2017),
ctivation and regulation
issue inhibitor of metalloproteinase 3 (TIMP3) is the only
nown endogenous inhibitor of TACE [8].
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Figure 1. TACE domains. Signal peptide (1-17 aa); pro-domain (18-214 aa) acting as an inactivator and a chaperone domain; extracellular
domain (215-671 aa) comprising: 1. A metalloprotease domain/catalytic domain (215-473 aa) responsible for an ectodomain shedding; 2. A
disintegrin domain (474-572 aa); 3. An EGF-like/cysteine rich domain (573-671 aa) responsible for substrate recognition and activation;
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Ttransmembrane domain (672-694 aa) necessary for effective clea
proteins that regulate TACE activity. aa: amino acid; EGF: endothelia
TIMP3  is  downregulated  in  circulating  human  monocytes
in  people  at  high  risk  of  diabetes  and  atherosclerosis  [9].
Stöhr  et  al.  demonstrated  that  TIMP3  also  regulates  lipid
metabolism  as  well  as  the  oxidative  stress  response,  main-
taining  metabolic  flexibility  in  the  heart,  particularly  during
episodes  of  increased  cardiac  stress  [10].  TIMP3  over  expres-
sion  has  been  shown  to  improve  post-myocardial  infarction
cardiac  remodelling  related  to  lower  extracellular  matrix
disruption  in  animal  models  [11,12].
Regarding  TIMP3  activation,  Cesaro  et  al.  showed  that
strong  TACE  expression  was  associated  with  early  acute
phase  inflammation  in  Crohn’s  disease,  whereas  TIMP3  was
upregulated  during  the  quiescent  phase  of  the  disease  [13].
TIMP3  may  therefore  be  involved  in  a  delayed  regulatory
mechanism  following  an  increased  TACE  expression,  and  its
role  in  inflammation  and  heart  related  diseases  should  be
studied  further.
Studies  have  shown  that  only  the  monomeric  form  of
TACE  is  active  and  can  effectively  cleave  its  substrates.  How-
ever,  TACE  appears  to  be  predominantly  present  as  dimers
at  the  cell  surface,  which  enables  its  efficient  association
with  TIMP3  and  silences  its  activity.  Hence,  TIMP3  inhibits
TACE  only  when  it  is  in  its  dimer  form.  Upon  activation  of
the  p38  mitogen-activated  protein  kinase  pathway,  the  bal-
ance  can  shift  from  TACE  dimers  to  monomers,  and  this  shift
is  associated  with  an  increase  in  cell  surface  presentation  of
TACE  and  a  reduction  in  TIMP3  association  [14].
Substrates and shedding process
TACE  mediates  cell-cell  interactions  with  a  wide  range  of
identified  substrates,  although  the  mechanisms  and  con-
sequences  of  this  binding  are  not  yet  fully  understood.
As  the  sequences  cleaved  in  various  substrates  are  highlyPlease  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Ro
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  d
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variable,  there  is  no  apparent  consensus  for  the  TACE  cleav-
age  sequence.  New  evidence  suggests  that  TACE  activity  is
regulated  by  its  non-catalytic  domains  and  the  secondary
structure  of  its  substrates  [15].
T
h
tof substrates; cytoplasmic domain (695-824 aa) binding to many
wth factor; TACE: tumour necrosis factor alpha converting enzyme.
Cleavage  of  TACE  substrates  occurs  at  extracellular  sites
roximal  to  the  cell  membrane,  thereby  releasing  the
oluble  ectodomain  from  the  cell  surface.  The  cleaved
olecules  can  then  bind  to  their  receptor  on  the  same
ell  (autocrine  effect)  or  to  receptors  on  neighbouring  cells
paracrine  effect)  or  even  enter  the  bloodstream  (endocrine
ffect).  When  the  substrate  is  cleaved  and  bound  to  its
eceptor,  it  can  initiate  downstream  signalling  events.  Alter-
atively,  the  receptor  can  also  be  cleaved  from  the  cell
urface;  thus,  ectodomain  shedding  can  actually  stop  the
igand-initiated  signalling.
Because  of  its  many  functional  properties,  TACE  plays  a
ajor  role  in  inflammation  through  its  shedding  of  a  vari-
ty  of  inflammatory  substrates.  Studies  have  shown  that
ACE  is  implicated  in  platelet  function  through  its  cleavage
f  the  von  Willebrand  factor  (CD42b)  receptor  [16].  TACE
s  also  responsible  for  the  cleavage  of  L-selectin  (CD62L),
ntracellular  adhesion  molecule  1  (ICAM-1)  and  vascular  cell
dhesion  protein  1  (VCAM-1)  [17].  Many  TACE  substrates
ave  been  extensively  investigated  in  atherosclerosis,  and
ll  are  known  to  participate  in  the  inflammatory  process
ccompanying  the  formation  and  progression  of  plaque
Fig.  3).  The  consequences  of  TACE  shedding  on  these  fac-
ors  needs  to  be  closely  investigated,  as  their  soluble  forms
ay  hold  different  properties  compared  to  their  membrane
orms.  For  example,  the  cleavage  of  TNFR1  by  TACE  sheds  a
oluble  form  of  TNFR1  that  binds  to  free  TNF, dampening
he  inflammatory  response  [18].  In  addition,  TACE  activates
igands  (such  as  neuregulin)  that  bind  to  the  ERbB  tyrosine
inase  family  of  receptors.  The  resulting  signalling  pathways
ave  been  involved  in  the  growth  of  many  tumour  types  as
ell  as  the  maintenance  of  cardiac  function  [19,20].
he fate of TACE after its activationle  of  tumour  necrosis  factor  alpha  converting  enzyme
isease  and  cardiac  events.  Arch  Cardiovasc  Dis  (2017),
here  appears  to  be  contradiction  in  the  understanding  what
appens  to  TACE  after  it  has  been  activated,  and  many  pos-
ulations  have  been  made.
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Figure 2. TACE activation and regulation. 1. Once synthesized, iRhom bind to TACE and promotes maturation, its exit from the endoplasmic
reticulum and its migration to the Golgi. 2. TACE prodomain is cleaved by furin in the trans-Golgi network. 3. During maturation, ERK-
dependent threonine 735 phosphorylation is necessary for TACE to reach the secretory pathway. 4. TACE is packaged into lipid rafts during
its transport and maturation through the Golgi. 5. Most of the active form of TACE is localized in the cellular perinuclear region, with a
small amount present in the plasma membrane. 6. TACE has an increased shedding rate when exposed to cell activators, such as phorbol
esters, including PMA. Other activators include lipopolysaccharide, which is dependent on ROS and the p38 MAPK pathway. 7. TACE is
present in dimers on the cell surface and binds to its inhibitor TIMP3. 8. Activation of the ERK or p38 MAPK pathway transforms TACE
from a dimer structure into a monomer structure and releases it from TIMP3. 9. TACE is regulated by FHL2 and SAP97. 10. TACE cleaves
transmembrane TNF and releases soluble TNF. ER: endoplasmic reticulum; ERK: extracellular signal-regulated kinases; FHL2: four and a
half LIM domains 2; LPS: lipopolysaccharide; iRhom2: rhomboid family member 2; MAPK: mitogen-activated protein kinases; PKC: protein
kinase C; PMA: phorbol myristate acetate; PTPH1: protein-tyrosine phosphatase; ROS: reactive oxygen species; SAP97: synapse-associated
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ADAM10,  another  member  of  the  ADAM  family,  is  known  to
ndergo  regulated  intramembrane  proteolysis  by  presenilin
fter  its  ectodomain  is  shed  by  ADAM-9  or  ADAM-15  [21].  InPlease  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Ro
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  d
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he  intramembrane  proteolysis  process,  a  membrane  pro-
ein  typically  undergoes  two  consecutive  cleavages.  The
rst  results  in  the  shedding  of  its  ectodomain;  the  second
ne  occurs  within  its  transmembrane  domain,  resulting  in
t
g
o
mnverting enzyme; TIMP3: tissue inhibitor of metalloproteinases 3;
ecretion  of  a  small  peptide  and  the  release  of  the
ntracellular  domain  into  the  cytosol.  After  intramem-
rane  proteolysis, the  cytoplasmic  domain  of  ADAM10  canle  of  tumour  necrosis  factor  alpha  converting  enzyme
isease  and  cardiac  events.  Arch  Cardiovasc  Dis  (2017),
ranslocate  to  the  nucleus  to  bind  to  gene  loci  under-
oing  transcription.  Since  ADAM10  is  the  closest  relative
f  TACE,  there  is  a  high  possibility  that  the  cytoplas-
ic  domain  of  TACE  itself  can  undergo  intramembrane
ARTICLE IN PRESS+ModelACVD-1047; No. of Pages 12
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Figure 3. Possible role of TACE in cardiac events. This diagram shows the different proteins cleaved by TACE that are involved in chronic
arterial wall inflammation occurring in atherosclerosis. As an example, TACE cleaves transmembrane TNF, TNFR1 and TNFR2 releasing their
soluble forms, sTNF, sTNFR1 and sTNFR2, respectively. The transmembrane ectodomain shedding combined with a premature endothelial
cell senescence due to TACE, leads to amplification of inflammation as well as reduction in endothelial health. This results in an increased
risk of plaque rupture and thrombosis, and an overall increased risk of developing cardiovascular events. sTNF: soluble tumour necrosis
factor alfa; sTNFR1: soluble tumour necrosis factor alfa receptor 1; sTNFR2: soluble tumour necrosis factor alfa receptor 2; TACE: tumour
TNF
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alfa receptor 1; TNFR2: tumour necrosis factor alfa receptor 2.
proteolysis  and  participate  in  gene  transcription  regula-
tion.  A  recent  study  reported  that  TACE  can  play  a role
in  post-myocardial  infarction  recovery  by  regulating  vascu-
lar  endothelial  growth  factor  receptor-2  transcription  and
angiogenesis  in  cardiomyocytes  [22].  Whether  TACE  is  inter-
nalized  and  downregulated  after  activation  is  still  unclear.
However,  recent  studies  have  reported  that  soluble  TACE  can
be  detected  in  the  plasma  [23,24],  which  is  suggestive  of  a
particular  mechanism  behind  its  own  shedding,  a  process
that  remains  unknown.
TACE and cardiovascular disease
TACE in heart diseasesPlease  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Ro
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  d
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Several  studies  have  investigated  the  role  of  TACE  in
heart  diseases.  Investigators  found  that  TACE  expression
was  increased  in  endomyocardial  tissues  in  myocarditis,
as  well  as  in  the  peripheral  blood  in  advanced  stages  of
a
o
s
e; TNF: tumour necrosis factor alfa; TNFR1: tumour necrosis factor
eart  failure.  TACE  was  upregulated  together  with  TNF
n  myocarditis  and  negatively  correlated  with  left  ventricu-
ar  systolic  function  [25].  Patients  with  advanced  congestive
eart  failure  also  had  an  increased  expression  of  TACE  and
NF compared  to  controls  [26]. The  role  of  TACE  has  been
ighlighted  in  aortic  aneurysm  [27]  and  in  heart  develop-
ent  [28]. Interestingly,  Takayanagi  et  al.  recently  reported
hat  TACE  may  be  a  novel  therapeutic  target  for  the  preven-
ion  of  hypertensive  complications  [29].
ACE and CAD
he  underlying  pathological  process  behind  the  develop-
ent  and  progression  of  CAD  is  atherosclerosis,  which  results
rom  an  imbalance  in  lipid  metabolism  and  a  maladaptive
mmune  response  leading  to  chronic  inflammation  in  thele  of  tumour  necrosis  factor  alpha  converting  enzyme
isease  and  cardiac  events.  Arch  Cardiovasc  Dis  (2017),
rterial  wall.  Major  adverse  cardiac  events  (MACE)  often
ccur  suddenly  in  patients  with  CAD  after  a  revascularization
trategy,  resulting  in  high  mortality  and  morbidity.  These
vents  include  death,  stroke,  myocardial  infarction,  heart
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ailure  and  repeat  coronary  revascularization  of  the  tar-
et  lesion  [30].  Many  studies  are  currently  investigating  the
ssociation  between  different  cardiovascular  markers  and
ACE  with  a  recent  interest  in  multiple  marker  models  ver-
us  a  single  marker  model  [31].  However,  the  investigation
f  TACE  and  associated  proteins  as  a  multiple  marker  model
or  MACE  prediction  has  not  yet  been  evaluated.
linical studies of TACE and associated
roteins in CAD and AMI
everal  studies  have  demonstrated  that  TACE  plays  a role
n  CAD  initiation  and  progression  to  an  acute  coronary  syn-
rome  (ACS).  Clinical  studies  have  shown  elevated  plasma
evels  of  TNF in  patients  with  AMI,  suggesting  that  TNF
aturation,  which  relies  on  TACE,  may  activate  systemic
nflammation  and  contribute  to  plaque  rupture  [32].  Sub-
equent  studies  have  found  a  positive  association  between
ACE  in  AMI,  as  summarized  in  Table  1.  Increased  levels  of
ene  expression  of  TNF  ˛ and  TACE  were  found  in  circulating
eucocytes  of  patients  with  myocardial  infarction,  obtained
ithin  24  hours  of  onset  [33].  The  Killip-Kamball  classifica-
ion  system  is  used  in  patients  with  an  ACS  to  stratify  their
isk  of  mortality  regarding  the  development  of  heart  fail-
re.  Expression  of  TACE  and  TNF  ˛ was  significantly  higher
n  patients  with  Killip-Kamball  class  III  or  IV  AMI  than  in
hose  with  class  I  or  II  AMI  or  in  controls  [34].  This  finding
emonstrates  that  higher  levels  of  TACE-associated  inflam-
ation  correlate  with  an  increased  risk  of  developing  severe
eart  failure  after  an  ACS.  Shimoda  et  al.  [35]  reported
hat  TACE  gene  expression  levels  in  peripheral  blood  cells
ere  higher  in  patients  with  AMI  compared  to  healthy  sub-
ects,  and  particularly  in  those  who  had  complications,  such
s  malignant  recurrent  ventricular  arrhythmia  or  pump  fail-
re.  Both  spontaneous  and  phorbol  12-myristate  13-acetate
PMA)-stimulated  levels  of  TACE  gene  expression  as  well  as
NF  gene  and  protein  expression  levels  were  found  to  be
igher  in  patients  with  AMI  compared  to  healthy  subjects.
ustained  increases  in  TACE  and  TNF levels  were  reported
4  days  after  the  onset  of  AMI  and  levels  correlated  posi-
ively  with  peak  creatinine  kinase  levels.
Systemic  gene  expression  levels  of  TACE  and  TNF  ˛ were
ocumented  to  be  higher  in  patients  with  AMI  compared  to
atients  with  stable  angina  [36].  Interestingly,  TACE  lev-
ls  were  higher  in  local  samples,  near  areas  of  ruptured
oronary  plaques,  than  in  systemic  samples  obtained  from
atients  with  AMI.  TACE  and  TNF immunostaining  showed
hat  they  were  localized  in  infiltrating  macrophages  in  rup-
ured  coronary  plaque/thrombus  materials  occluding  the
ulprit  coronary  artery.  In  addition,  increased  levels  of  TACE
n  culprit  coronary  samples  were  the  strongest  independent
redictor  of  adverse  cardiac  events  (6  months  after  the
nset  of  AMI)  after  adjustment  for  various  clinical  variables.
he  authors  suggested  that  local  expression  of  TACE  in  the
ulprit  coronary  artery  leads  to  arterial  remodelling  and  rup-
ure  or  erosion  of  weakened  coronary  plaque,  leading  to  the
xacerbation  of  cardiac  events  [36].
Rizza  et  al.  [37]  recently  measured  TACE  activity  byPlease  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Ro
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  d
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valuating  the  levels  of  its  main  four  substrates  (soluble
CAM-1,  soluble  ICAM,  soluble  IL6R  and  soluble  TNFR1)  in
ubjects  with  established  vascular  atherosclerosis  who  were
ollowed  for  secondary  MACE.  They  identified  three  homo-
d
T
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eneous  subgroups  of  patients,  in  terms  of  event  risk,  and
n  increased  risk  for  incident  events  was  observed  among
ndividuals  with  a  high  TACE  score.  Looking  closely  at  TNF
eceptors,  soluble  TNFR2  levels  were  found  to  be  increased
n  heart  failure,  and  other  studies  have  shown  higher  circu-
ating  levels  of  soluble  TNFR1  and  soluble  TNFR2  associated
ith  nephropathy,  cardiovascular  events,  and  total  mortal-
ty  in  type  2  diabetes  [38].  Canault  et  al.  demonstrated  that
ACE-containing  microparticles  of  atherosclerotic  plaques
re  partly  of  endothelial  origin  and  that  TACE  on  the  sur-
ace  of  microparticles  was  still  active  [39]. A  more  recent
tudy  showed  TACE  activity  in  the  plasma  of  patients
ith  anti-neutrophil  cytoplasmic  autoantibodies  vasculi-
is  and  indicated  that  TACE  was  also  present  on  plasma
icroparticles  derived  mainly  from  platelets  but  also  from
ndothelial  cells.  The  authors  reported  that  it  is  the  active
orm  of  TACE  that  is  detectable  in  plasma  samples  and  that
t  is  found  on  the  surface  of  microparticles  originating  from
latelets  as  well  as  endothelial  cells  [24].
Other  studies  have  investigated  the  role  of  TACE  poly-
orphisms  in  relation  to  cardiovascular  disease.  In  the
therogene  study,  TNF, soluble  TNFR1,  and  soluble  TNFR2
oncentrations  were  all  significantly  elevated  in  patients
ith  future  cardiovascular  death.  Moreover,  individuals  car-
ying  the  747Leu  allele  in  TACE  displayed  a borderline
ncreased  risk  of  future  cardiovascular  death.  This  study  also
uggests  a role  of  TACE  in  the  regulation  of  TNF plasma  lev-
ls  and  identified  the  TACE  gene  as  a  candidate  for  CAD  risk
40].
ACE activation in CAD
he  association  of  TACE  with  CAD  is  due  first,  to  its  role  in
hedding  a variety  of  inflammatory  molecules  (Fig.  3)  and
econd,  to  some  of  its  activators  that  have  been  shown  to
e  associated  with  atherosclerosis  and  pathophysiological
unctions  in  CAD.
TACE  has  an  increased  shedding  rate  when  exposed  to  cell
ctivators,  such  as  phorbol  esters  (e.g.  PMA)  [41],  the  p38
APK  pathway  and  lipopolysaccharide,  which  is  dependent
n  reactive  oxygen  species  stimulation  [42]. Oxidative  stress
enerating  reactive  oxygen  species  is  known  to  be  involved
n  the  progression  of  atherosclerosis,  disturbed  blood  flow
nd  arterial  wall  remodelling  [43].  When  reactive  oxygen
pecies  are  generated,  TACE  activation  is  increased  as  a
esult  local  and  systemic  inflammation.  Moreover,  it  is  known
hat  nitric  oxide  can  activate  TACE  [44].  Nitric  oxide  is
nvolved  in  the  physiological  regulation  of  blood  flow  and
as  pathophysiological  functions  in  CAD  [44].  On  the  other
and,  C-reactive  protein  is  also  known  to  activate  TACE
nd  the  release  of  soluble  lectin-like  oxidized  low-density
ipoprotein  receptor-1,  which  plays  an  important  role  in  the
evelopment  and  progression  of  atherosclerosis  [45].  There-
ore,  TACE  is  not  one  inflammatory  factor  among  many,  but  is
 key  enzyme.  Its  activators  and  subsequently  shed  proteins
re  essential  mediators  in  the  development  and  progression
f  CAD  (Fig.  3).
ACE, associated proteins and endothelialle  of  tumour  necrosis  factor  alpha  converting  enzyme
isease  and  cardiac  events.  Arch  Cardiovasc  Dis  (2017),
ysfunction in CAD
NF is  a major  contributor  to  inflammatory  processes
n  CAD.  On  cleavage  of  transmembrane  TNF by  TACE,
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Table  1 Summary  of  studies  of  TACE  and  associated  proteins,  and  their  clinical  implications  in  cardiovascular  disease.
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary  Reference
Heart  disease:  animal  studies
Mouse
(atherosclero-
sis)
Atherosclerotic
lesions
IHC
FC
ELISA
Five-week-old  apoE−/− male
mice  examined  at  5,  10,  15
and  25  weeks  of  age  (14  in
each  group)  and  wild-type
mice  (n  =  6)  were  fed  a
high-fat  diet
Strong  expression  of  TACE  in
atherosclerosis-prone  sites  (aortic  sinus  and
arch)
Plasma  levels  of  sTNFR1  and  sTNFR2  correlated
with  atherosclerotic  severity
Canault  et  al.,  2006  [63]
Timp3−/−
mouse
Heart  tissue
samples
qPCR
WB
TIMP3-deficient  mice  (n  =  11)
Age-matched  wild-type
littermates  (n  =  9)
Loss  of  TIMP3  function  triggered  spontaneous
left  ventricular  dilatation,  cardiomyocyte
hypertrophy,  and  contractile  dysfunction  at
21  months  of  age
Fedak  et  al.,  2004  [33]
Rabbit  Sections  from
abdominal  aorta
Macrophages
Tissues  and  cell
lysate
IF
qPCR
WB
55  adult  male  New  Zealand
white  rabbits  and  were  then
divided  into  3  groups
TACE  gene  silencing  reduced  remodelling  index
and  plaque  burden  and  diminished  the  content
of  macrophages  and  lipids  while  increased  that
of  smooth  muscle  cells  and  collagen  in  the
aortic  plaques
The  expression  levels  of  TACE  in  unstable
plaques  were  significantly  higher  than  in  stable
plaques  (42.6  ±  7.6  vs  25.2  ±  6.5%,  P  <  0.01)
Zhao  et  al.,  2015  [64]
Heart  disease:  human  studies
Atheroscle-
rosis
Surface  of
microparticles
FC
IHC
25  patients  (symptomatic,
n  =  10;  asymptomatic,  n  =  15)
undergoing  carotid
endarterectomy  3  controls
Human  plaque  microparticles  carried
catalytically  active  TACE  and  significantly
enhanced  the  cell  surface  processing  of  the
TACE  substrates  TNF, TNFR1  and  endothelial
protein  C  receptor
Canault  et  al.,  2007  [39]
Myocarditis  Endomyocardial
biopsy  tissues
qPCR
IHC
14  patients
5 controls
TNF and  TACE  expression  was  significantly
greater  in  the  myocarditis  group  than  in  the
control  group  (P  <  0.05)
Satoh  et  al.,  2000  [25]
CHF  PBMC  qPCR
FC
46  patients
22  controls
TACE  and  TNF gene  expression,  intracellular
TACE  and  TNF flow  cytometry  staining,  and
supernatant  TNF were  higher  in  CHF  patients
than  in  controls  (P  <  0.001)
Satoh et  al.,  2004  [26]
AAA  Aortic  sample IHC  39  patients
8 controls
TACE  gene  expression  was  increased  in  human
AAA  samples  compared  with  normal  aorta
Kaneko  et  al.,  2011  [27]
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Table  1  (Continued)
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary  Reference
AMI  within
24  h  of  onset
Circulating
leukocytes
qPCR  37  patients
8  controls
TACE.  TNF gene  expression  was  higher  in
circulating  leucocytes  in  AMI  patients
compared  with  controls  (P  <  0.01)
Akatsu  et  al.,  2003  [34]
AMI  (blood
samples  on
day  1  and
day  14  after
onset  of
myocardial
infarction)
PBMC  qPCR
FC
41  patients
15  controls
TACE  and  TNF gene  expression  levels  were
higher  in  AMI  patients  than  in  healthy  controls
(P  <  0.001)
Levels  of  TACE  and  TNF decreased  14  days
after  the  onset  of  AMI
The  percentage  of  TACE  and  TNF cells  with
positive  staining  was  higher  in  AMI  patients
compared  with  healthy  controls  (P  <  0.001)
Shimoda  et  al.,  2005  [35]
AMI  Local  samples
from  the  plaque
site
Systemic  samples
from  the  aorta
Thrombus
material
qPCR
FC
IHC
60  AMI  patients
21  stable  angina  patients
TACE  and  TNF gene  expression  and  protein
levels  in  both  local  and  systemic  samples
obtained  from  AMI  patients  were  higher  than
those  levels  in  systemic  samples  obtained  from
stable  angina  patients  (P  <  0.001)
In  AMI  patients,  these  levels  were  higher  in
local  samples  than  in  systemic  samples
(P  <  0.001)
By  the  6-month  follow-up  study,  local  TACE
levels  remained  the  only  significant
independent  predictor  of  adverse  cardiac
events  in  AMI
Satoh  et  al.,  2008  [36]
Acute  stage
of  atheroscle-
rotic
ischaemic
stroke
Platelet-rich
plasma  and
platelet  total
protein  samples
WB  306  patients
230  controls
Plasma  TACE  levels  in  the  atherosclerotic
ischaemic  stroke  group  were  higher  than  those
in  the  control  group  (P  =  0.70,  P  =  0.000)
Ling  et  al.,  2013  [65]
Human
atheroscle-
rotic
plaques
Surgical  waste
from
endarterectomy
pieces
IHC  4  human  atherosclerotic
plaques
TACE  gene  expression  was  observed  in  human
atherosclerotic  plaques
Canault  et  al.,  2007  [39]
Cardiac
surgery  with
cardiopul-
monary
bypass
Plasma  sample  at
three  time
points:  before
anaesthesia,  at
the  beginning  of
sternal  wiring,
48  h  after  the
first  sample
ELISA  25  patients  Analysis  of  TACE  activity  did  not  show
significant  differences  between  the  different
time  points  (P  =  0.40),  but  a  trend  of  the
medians  was  apparent  towards  higher  values
postoperatively  and  after  48  hours
Erdoes  et  al.,  2013  [66]
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Table  1  (Continued)
Model/disease  Site  of  TACE
measurement
Methods  Animals  Results  summary Reference
Other  diseases:  human  studies
MCI  and  AD Cerebrospinal
fluid  and  human
plasma
FRET
WB
64  patients  with  AD,
88  subjects  with  MCI,  and
50  age-matched  healthy
controls
Plasma  TACE  protein  levels  did  not  differ
significantly  in  the  three  study  groups.
However,  plasma  TACE  activity  in  subjects  with
MCI  and  AD  patients  was  significantly  higher
than  that  in  HC  (P  <  0.001)
TACE  enzymatic  activity  may  increase
progressively  over  the  clinical  course  of  AD
Sun  et  al.,  2014  [23]
AAV Plasma  samples ELISA
FRET
FC
IHC
PR3-AAV  active  (n  =  47)
PR3-AAV  remission  (n  =  45)
Disease  control  (n  =  14)
TACE  protein  levels  were  significantly  increased
in  plasma  samples  from  patients  with  active
PR3-AAV  compared  with  samples  from  patients
in  remission  or  from  other  controls  with  renal
nonvascular  diseases
Plasma  TACE  retained  its  specific  proteolytic
activity  and  was  partly  located  on  extracellular
microparticles
Transcript  levels  of  TACE  were  increased  in
blood  samples  of  patients  with  active  AAV
Bertram  et  al.,  2015  [24]
Clinical
malaria
Plasma  samples ELISA  Village  infections  (n  =  6),
uncomplicated  malaria
(n  =  39),  severe  malaria
(n  =  123),  non-malaria
hospitalized  (n  =  32),  Acute
severe  malaria/convalescent
(n  =  19)
Plasma  levels  of  TACE  were  increased  in
Tanzanian  children  hospitalized  with  a  malaria
infection  compared  with  asymptomatic
children,  but  were  similar  to  children
hospitalized  with  other  infectious  diseases
Plasma  levels  of  TACE  decreased  during
recovery  after  an  acute  malaria  episode
Petersen  et  al.,  2016  [67]
AAA: abdominal aortic aneurysm; AAV: active proteinase-3 (PR3)-positive ANCA-associated vasculitis; AD: Alzheimer’s disease; AMI: acute myocardial infarction; ANCA: antineutrophil
cytoplasmic autoantibodies; CHF: congestive heart failure; ELISA: enzyme-linked immunosorbent assay; FC: flow cytometry; FRET: fluorescent resonance energy transfer; IF:
immunofluorescence; IHC: immunohistochemistry assay; MIC: mild cognitive impairment; PBMC: peripheral blood mononuclear cells; qPCR: real time polymerase chain reaction; TIMP3:
metalloproteinase inhibitor 3; TNF: tumour necrosis factor alpha; TNFR1: TNF receptor type 1; TNFR2: TNF receptor type 2; sTNFR1: soluble TNFR1; sTNFR2: soluble TNFR2; WB:
western blot.
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pregulation  of  TNF can  promote  premature  endothe-
ial  cell  senescence  and  can  participate  in  the  ageing
rocess  of  coronary  arteries  [46].  Recently,  endogenous
ransmembrane  TNF was  shown  to  protect  against  prema-
ure  senescence  in  endothelial  colony  forming  cells  [47].
his  is  supported  by  a  murine  study  in  which  transgenic
ice  that  only  express  an  uncleavable  version  of  transmem-
rane  TNF developed  fewer  inflammatory  atherosclerotic
laques  than  the  wild-type  mice  [48].
It  has  been  also  reported  that  TNFR1  activates  multi-
le  signalling  pathways  that  have  been  linked  to  apoptosis,
ndothelial  cell  dysfunction  and  inflammation,  whereas
NFR2  signalling  has  been  proven  to  be  beneficial  to  the
ardiovascular  system  by  activating  angiogenic  and  survival
athways  [49].  Transmembrane  TNF has  a  higher  affinity  for
NFR2,  which  confers  a  survival  signal,  mediating  angiogenic
nd  blood  vessel  repair  activities  [50].  This  suggests  that
ransmembrane  TNF cleavage  by  TACE  can  have  a  deleteri-
us  effect  on  the  protective  and  repair  function  properties
rovided  by  transmembrane  TNF. The  role  of  TACE  in  vas-
ular  dysfunction  was  also  highlighted  in  patients  and  mice,
here  ageing  and  obesity  cooperatively  reduced  caveolin-1
xpression  and  increased  vascular  endothelial  TACE  activ-
ty  and  soluble  TNF release  in  adipose  tissue.  This  was
elieved  to  contribute  to  the  development  of  remote  coro-
ary  microvascular  dysfunction  in  older  obese  patients  [46].
ACE inhibition
s  TACE  seems  to  be  implicated  in  many  physiologi-
al  processes,  it  is  important  to  consider  its  inhibition
nd  the  potential  consequences.  Interestingly,  a  patient
ith  homozygous  TACE  deficiency  was  identified  [52]  who,
espite  repeated  skin  infections  and  episodes  of  bowel  dis-
ase,  led  a  relatively  normal  life,  indicating  that  loss  of
ACE  in  humans  might  have  less  severe  consequences  than
n  rodents  [53].  The  most  promising  TACE  inhibition  (with-
ut  any  major  physiological  consequences)  seems  to  lie  in
he  inhibition  of  its  regulators.  iRhom1  and  2  are  needed
or  TACE  transport  to  the  cell  surface  (Fig.  2)  and  it  is
ell  established  that  iRhom2  is  predominantly  expressed  in
mmune  cells,  such  as  neutrophils  and  macrophages  [54],
hereas  iRhom1  is  mostly  expressed  on  non-immune  cells
55].  Therefore,  it  is  tempting  to  speculate  that  inhibition  of
Rhom2  would  lead  to  a  selective  deficiency  of  TACE  in  neu-
rophils  and  macrophages  with  no  effects  on  keratinocytes
r  intestinal  epithelial  cells  where,  in  these  cell  types,
Rhom1  would  compensate  for  the  blockade  of  iRhom2.
ecently,  it  was  found  that  reducing  the  release  of  TNF in
ardiomyocytes  by  pharmacologically  attenuating  the  phos-
horylation  of  TACE,  reduced  TNF shedding  activity  by
ACE  [56].  It  was  also  proven  possible  to  inhibit  specifi-
ally  TACE  activity  by  using  its  natural  inhibitory  domain
nd  consequently  modulating  TNF secretion  in  cells  [57].
nother  strategy  of  inhibiting  TACE  could  be  an  injection  of
ts  inhibitor  TIMP3  in  the  heart,  which  has  been  shown  to  pre-Please  cite  this  article  in  press  as:  Chemaly  M,  et  al.  Ro
(TACE/ADAM17)  and  associated  proteins  in  coronary  artery  d
https://doi.org/10.1016/j.acvd.2017.08.002
ent  heart  failure  post-myocardial  infarction  [58].  However,
ince  TACE  inhibition  will  reduce  TNF activity,  it  is  impor-
ant  to  consider  the  complex  cardiac  effects  observed  after
NF inhibition  as  it  is  becoming  increasingly  clear  that  a PRESS
M.  Chemaly  et  al.
inimum  level  of  TNF is  important  for  the  normal  function
f  the  heart  [59,60].
uture work and conclusions
ACE  plays  a  major  role  in  controlling  inflammatory  pro-
esses  and  is  involved  in  several  chronic  diseases.  The
umber  of  known  TACE  substrates  continues  to  increase,
ith  mounting  evidence  that  TACE  is  implicated  in  many  cel-
ular  functions.  Recent  research  indicates  a  particular  role
or  TACE  and  the  TNF  family  members  in  CAD  and  cardiovas-
ular  events,  but  none  have  really  looked  at  this  panel  from
 biomarker  development  point  of  view.  Further  investiga-
ions  are,  however,  required  to  ascertain  the  exact  role  and
echanism  of  action  of  TACE  in  this  disease  area.
Future  prospective  studies  in  clinical  cohorts  at  vary-
ng  degrees  of  cardiovascular  risk  stratification  are  needed
o  fully  assess  TACE  as  a potential  biomarker  for  CAD  and
ACE  risk.  This  will  be  crucial  for  the  future  development
f  new  personalized  predictive  tests  and  therapeutics  that
an  improve  patient  clinical  care  pathways  and  prevent  the
igh  mortality  rates  associated  with  CAD.
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